BRAT1: A Potent Drug Target and Biomarker for Breast Cancer (G221927)

Target Name: BRAT1

NCBI ID: G221927

BRAT1

BRAT1: A Potent Drug Target and Biomarker for Breast Cancer

Abstract:BRAT1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for breast cancer.BRAT1 has been shown to play a critical role in the development and progression of breast cancer by regulating the cell cycle, promoting the growth and survival of cancer cells, and inhibiting the efficacy of anti-cancer drugs.Furthermore,BRAT1 has been shown to be overexpressed in various types of breast cancer, including hormone receptor-positive and hormone receptor-negative tumors.These findings suggest that targeting BRAT1 may be an effective strategy for the treatment of breast cancer.

Introduction:Breast cancer is a leading cause of cancer-related deaths in women worldwide.According to the World Health Organization (WHO), it is estimated that there will be 218,000 new cases of breast cancer cases and 52,000 deaths in the United States in 2020.Breast cancer is a complex disease that arises from a combination of genetic and environmental factors.It is characterized by the formation of abnormal cells in the breast tissue, which can evolve into invasive or metastatic tumors.There are several treatment options available for breast cancer, including surgery, radiation therapy, and chemotherapy.However, the majority of breast cancers are not responsive to these treatments, leading to a need for new and more effective therapies.

BRAT1:A Non-Coding RNA Molecule

BRAT1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for breast cancer.It is expressed in various tissues and cell types, including breast tissue, and has been shown to play a critical role in the development and progression of breast cancer.

BRAT1 regulates the cell cycle by inhibiting the kinetic properties of the centromere, which is the region of the chromosome that separates the replicated copies of the chromosome during the cell cycle.By inhibiting the function of the centromere,BRAT1 has been shown to slow down the movement of chromosomes during the cell cycle, leading to the accumulation of genetic alterations that can lead to the formation of cancer cells.

BRAT1 also promotes the growth and survival of cancer cells by inhibiting the programmed cell death (apoptosis) mechanism.In cancer cells, apoptosis is a natural response to the growth and survival of cancer cells, but in BRAT1-positive breast cancer cells, apoptosis is aberrate, leading to the survival and proliferation of cancer cells.

BRAT1 also inhibits the efficacy of anti-cancer drugs by modulating the expression of genes involved in drug resistance.These findings suggest that targeting BRAT1 may be an effective strategy for the treatment of breast cancer.

BRAT1 Overexpression in Breast Cancer

BRAT1 has been shown to be overexpressed in various types of breast cancer, including hormone receptor-positive and hormone receptor-negative tumors.Hormone receptor-positive breast cancers, which account for about 80% of all breast cancers, are characterized by the presence of hormone receptors on the surface of the cancer cells, such as estrogen receptors (ER) and progesterone receptors (PR).These cancers can be treated with hormone therapies, such as hormone receptor-lowering drugs, to inhibit the effects of hormones.

Hormone receptor-negative breast cancers, which account for about 20% of all breast cancers, do not have hormone receptors and are less sensitive to hormone therapies.However, these cancers can still be treated with chemotherapy, which is a broad

Protein Name: BRCA1 Associated ATM Activator 1

Functions: Involved in DNA damage response; activates kinases ATM, SMC1A and PRKDC by modulating their phosphorylation status following ionizing radiation (IR) stress (PubMed:16452482, PubMed:22977523). Plays a role in regulating mitochondrial function and cell proliferation (PubMed:25070371). Required for protein stability of MTOR and MTOR-related proteins, and cell cycle progress by growth factors (PubMed:25657994)

The "BRAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets